Policy desk · News analysis
October 2026 peptide compounding policy: scope and limits
Read the policy conditions, the company announcement and the questions to take to your prescriber.
What the October policy covers
October 29: HHS describes conditional interim 503A enforcement discretion for six peptide forms and routes; inclusion does not establish that a compounder qualifies. Sources: 1
This is a 503A policy, not a 503B authorization. Sources: 1
The dates and legal status
The Federal Register public-inspection notice was filed October 28 at 11:15 a.m. On October 29 it remained unpublished, with publication scheduled for October 30. It describes the policy as draft and nonbinding, with comments due two weeks after publication. Sources: 2
The notice concerns an interim policy while the permanent list develops through rulemaking. It is not a final list decision, and HHS may revisit the policy over safety or quality concerns. Sources: 2
Which forms and routes are listed?
BPC-157 intravenous use is outside these routes; TB-500 is not full-length thymosin beta-4. Sources: 1
Forms and routes
On smaller screens, scroll the table horizontally. Keyboard users can focus the table region and use the arrow keys.
| Form | Route |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical |
| Epitalon acetate | Subcutaneous or intramuscular; intermittent courses |
| KPV acetate | Topical or oral |
| MOTS-c acetate | Subcutaneous or intramuscular |
| Semax free base | Intranasal |
| TB-500 acetate | Subcutaneous or intramuscular |
Policy conditions: reading index
- A listed substance.
- The specified identity and route.
- FDA-registered source; valid certificate of analysis.
- Original bulk manufacturer's FDA registration, CGMP and site address on certificate; FDA-registered intermediaries must validate vendors and certificates.
- Products, serious events regardless of causality, and quality issues reported to FDA and relevant states; reporting instructions on labels.
- Label identifying compounding and prohibiting resale.
- One listed active ingredient.
- Documentation of adequate human oral bioavailability for the specific formulation.
- Only 510(k)-cleared syringes as co-packaged or drug-containing delivery devices.
- Other federal requirements, sanitation and patient-specific prescriptions.
Questions to ask about an offer
When asking about an offer, keep its exact name, route, dispensing pharmacy and date together. Request records tied to that offer rather than a general assurance. This article has not inspected a pharmacy or tested a preparation.
What Hims announced
Hims & Hers' October 29 announcement previews Peptides+. Its plans name Sermorelin, Glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 deferred until allowable. Sources: 3
The company describes independent prescribers and licensed dispensing pharmacies. Its forward-looking disclaimer covers launch timing and availability. A preview and stated plan do not demonstrate an order, eligibility decision, dispensing event or delivery. This report has not verified those events or a launch date. Sources: 3
The Hims & Hers review retains its August GLP-1 scope. The new announcement does not refresh that earlier review.
Approval, benefit and pharmacy oversight
FDA distinguishes approved generics from compounded medicines: a generic must satisfy approval requirements, including therapeutic equivalence, while a compounded drug has no FDA premarket approval. Poor compounding can produce contamination or incorrect strength. State boards generally lead routine oversight of non-outsourcing pharmacies; FDA can also inspect them. Registered 503B outsourcing facilities are primarily FDA-overseen and subject to current good manufacturing practice. Finished drugs compounded in accordance with 503A are exempt from those CGMP requirements; other federal requirements still apply. Sources: 4
FDA also cautions that online customers may not know who actually compounded their medicine. Identifying the platform alone does not identify the compounder. Ask for the dispensing pharmacy's name and its regulatory identity. Sources: 4
A policy decision does not establish a treatment benefit. Ask your prescriber which evidence addresses your health goal and circumstances; the peptide library keeps its clinical source notes separate. Sources: 4
How to read the older coverage
The earlier retatrutide and peptide article carries a separate policy notice. Its untouched clinical reporting, provider descriptions and discussions of other compounds retain their August context; they were not reassessed for this update.
Questions about this update
Is this FDA approval?
No. Compounded drugs do not undergo FDA premarket approval. Policy eligibility and a product’s clinical benefit require separate evidence. Sources: 4
Can I order Peptides+ now?
Not established by this announcement. It previews a planned service; we have not verified an order, dispensing or delivery. Sources: 3
Does this update replace the older clinical reviews?
No. The linked notices add policy context; existing clinical fields and source-check dates remain unchanged.
Editorial assessment
Take questions about your own care to a qualified clinician, and questions about an offer to the named dispensing pharmacy. This article cannot decide suitability or compliance for you.
Source documents
- HHS peptide policy document · U.S. Department of Health and Human Services · Checked 2026-10-29
- Federal Register public-inspection notice 2026-22192 · Federal Register · Checked 2026-10-29
- Hims & Hers announcement, October 29 · Hims & Hers · Checked 2026-10-29
- FDA questions and answers about compounding · U.S. Food and Drug Administration · Checked 2026-10-29